IBC Ab002
Alternative Names: IBC-Ab002Latest Information Update: 30 Oct 2025
At a glance
- Originator ImmunoBrain Checkpoint
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
- Research Neurodegenerative disorders
- Discontinued Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 30 Oct 2025 Discontinued - Preclinical for Amyotrophic lateral sclerosis in Israel (Parenteral) (ImmunoBrain Checkpoint pipeline, October 2025)
- 30 Oct 2025 Discontinued - Preclinical for Frontotemporal dementia in Israel (Parenteral) (ImmunoBrain Checkpoint pipeline, October 2025)
- 29 Sep 2025 IBC Ab002 is still in phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in Israel, Netherlands, United Kingdom (IV) (NCT05551741)